Methasteron-associated cholestatic liver injury: clinicopathologic findings in 5 cases

Clin Gastroenterol Hepatol. 2008 Feb;6(2):255-8. doi: 10.1016/j.cgh.2007.11.010. Epub 2008 Jan 9.


Background & aims: Methasteron is a nutritional supplement used to increase weight or accelerate the build-up of muscle mass. The aim of this study was to describe 5 cases of hepatotoxicity in patients using methasteron seen at tertiary-care medical centers.

Methods: A case report design was used.

Results: Five previously healthy patients who used methasteron developed jaundice 2 weeks after discontinuation; they presented to a tertiary-care medical center 2 weeks later. Within another 2 to 3 weeks, bilirubin levels peaked. About 12 weeks after initial presentation, all cases resolved with no identifiable residual hepatic dysfunction.

Conclusions: Methasteron use can result in severe hepatotoxicity. Liver failure can worsen after initial presentation, especially within 2 weeks. With close observation and supportive care, acute hepatic injury should resolve.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Bilirubin / blood
  • Cholestasis, Intrahepatic / chemically induced*
  • Cholestasis, Intrahepatic / complications*
  • Dietary Supplements / adverse effects*
  • Humans
  • Jaundice, Obstructive / chemically induced
  • Jaundice, Obstructive / diagnosis
  • Liver Diseases / diagnosis*
  • Liver Diseases / pathology
  • Liver Diseases / physiopathology
  • Male


  • Bilirubin